Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bountiful Approvals May Be Ahead As FDA Starts 2023 With Almost 60 Novel Agents Under Review

Feb 06 2023

• By Bridget Silverman

• Source: Shutterstock

Related Content

Hot Spots In 2023: US FDA Goal Dates Portend Battles In Diseases From RSV To Ulcerative Colitis

Feb 06 2023

Too Big To Succeed? Cytokinetics Heart Failure Trial Proves Too Much For FDA Committee

Dec 20 2022

Sanofi/Sobi’s Next-Gen Factor VIII Therapy BLA Heats Up Biotech-Driven Hemophilia Arms Race

Jul 18 2022

Related Companies

Eisai Co., Ltd.

Biogen, Inc.

Eli Lilly and Company

TheracosBio, LLC

Stemline Therapeutics, Inc.

GSK plc

uniQure N.V.

CSL Limited

BioMarin Pharmaceutical Inc.

Sanofi

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

CRISPR Therapeutics AG

Cytokinetics, Inc.

Lexicon Pharmaceuticals, Inc.

Travere Therapeutics, Inc.

Johnson & Johnson

Genentech, Inc.

Genmab A/S

Checkpoint Therapeutics, Inc.

Additional Topics

United States Drug Review Drug Approval Standards Regulation Pink Sheet Perspectives US FDA Performance Tracker BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window